BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the appointment of Jeffrey W. Winkelman, Ph.D., J.D. as vice president, oncology programs. His primary responsibilities will be management of BioSante’s oncology products including collaborations with John Hopkins Sidney Kimmel Cancer Center, contracts, licensing and intellectual property. “We are very pleased that Jeff has agreed to join BioSante,” said Stephen M. Simes, president and CEO of BioSante. “Jeff brings a wide range of experience especially related to BioSante’s recently acquired GVAX vaccines and related technologies. He also is experienced in the areas of intellectual property, contracts and business development activities. We believe Jeff will prove valuable for BioSante in many ways including maximizing the value of these newly acquired technologies. Since Jeff was a vice president at Cell Genesys before we acquired that company, and very involved in all aspects of the business, Jeff is familiar with all acquired products and technologies as well as with the 95 patents and 85 patent applications that cover the newly acquired technologies as a result of the acquisition.” Dr. Winkelman is a Ph.D. in molecular genetics and is a registered attorney with the United States Patent and Trademark Office, and has over 15 years of experience handling a broad range of clinical development and intellectual property and licensing matters. Most recently, Dr. Winkelman was an independent consultant providing counseling and advice for a number of biotechnology and pharmaceutical companies, including BioSante. From 2004 to 2008, Dr. Winkelman was a vice president, at Cell Genesys, Inc., overseeing intellectual property and licensing activities. Prior to that, Dr. Winkelman has held several in-house, senior management positions at biotechnology companies as well as worked as an associate attorney at an intellectual property law firm. Dr. Winkelman received his Ph.D. in Molecular Genetics from University of California - Irvine and his law degree from University of San Diego.
About BioSante Pharmaceuticals, Inc.BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel ® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals (NASDAQ: TEVA) and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), as a vaccine adjuvant, including for an H1N1 (swine flu) vaccine, and drug delivery. In addition, BioSante will seek opportunities for its GVAX cancer immunotherapies, 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com. This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this news release that are not historical in nature, particularly those that utilize terminology such as “will,” “potential,” “continue,” “could,” “should,” “believe,” ”intends,” “plans,” “expects” or comparable terminology, are forward-looking statements. Examples of forward-looking statements in this news release include statements regarding the continued role of Dr. Winkelman in BioSante’s efforts and the potential value of those efforts. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that could cause actual results to differ materially from those expressed in such forward-looking statements include the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, the success of clinical testing, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent annual report on Form 10-K and Form 10Q, which discussions also are incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.